In a disclosure to the Hong Kong Stock Exchange, Insilico Medicine revealed that it has forged an exclusive licensing and joint development partnership with Shenzhen Hengtai Biopharma Co., Ltd. concerning the ISM8969 project. ISM8969 represents a cutting-edge, orally administered NLRP3 inhibitor capable of penetrating the blood-brain barrier, specifically designed for the management of central nervous system disorders.

According to the terms of the agreement, Insilico Medicine will bestow upon Hengtai Biopharma the worldwide rights to conduct research, develop, register, produce, and market ISM8969, with both entities sharing an equal 50% stake in the project's global rights. Furthermore, Insilico Medicine is set to receive an initial payment as well as milestone payments, collectively amounting to up to US$66 million (roughly HK$514.8 million). This includes an immediate payment of US$10 million (approximately HK$78 million), which is to be remitted within 30 days of the agreement's activation.